AGLE insider filings

Spyre Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-11-28. Screen AGLE transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for AGLE between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Spyre Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2023-11-284Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund L.P. — Director, 10% owner
Fairmount Healthcare Fund II L.P. — Director, 10% owner
Fairmount Healthcare Co-Invest L.P. — Director, 10% owner
Kiselak Tomas — Director, 10% owner
Harwin Peter Evan — Director, 10% owner
Conversion (C): 3,435,480 @ $0 · Conversion (C): 85,887 (derivative) @ $0EDGAR
2023-11-274Albers Jeffrey W. — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2023-11-274Stelzer Laurie — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2023-11-274Turtle Cameron — Chief Executive Officer, DirectorConversion (C): 723,440 @ $0 · Grant/award (A): 374,000 (derivative) @ $0 · Conversion (C): 18,086 (derivative) @ $0EDGAR
2023-09-054King-Jones Heidy — See RemarksGrant/award (A): 13,495,255 (derivative) @ $0EDGAR
2023-09-054Burrows Scott L — Chief Financial OfficerGrant/award (A): 10,121,441 (derivative) @ $0EDGAR
2023-06-304Alspaugh Jonathan — President and CFOGrant/award (A): 19,787,969 (derivative) @ $0EDGAR
2023-06-304Smith Hunter C — DirectorGrant/award (A): 1,950,000 (derivative) @ $0EDGAR
2023-06-304Lawton Alison Frances — DirectorGrant/award (A): 1,950,000 (derivative) @ $0EDGAR
2023-06-304Cox Russell J. — DirectorGrant/award (A): 1,950,000 (derivative) @ $0EDGAR
2023-06-304Magovcevic-Liebisch Ivana — DirectorGrant/award (A): 1,950,000 (derivative) @ $0EDGAR
2023-02-244Neuman Linda L — Chief Medical OfficerGrant/award (A): 550,000 (derivative) @ $0EDGAR
2023-02-244Kastenmayer James Paul — General CounselGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-02-244Hanley Jr. Michael Conick — Chief Business OfficerGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-02-244Alspaugh Jonathan — Chief Financial OfficerGrant/award (A): 640,000 (derivative) @ $0EDGAR
2023-01-274Neuman Linda L — Chief Medical OfficerGrant/award (A): 25,000 (derivative) @ $0EDGAR
2022-12-014Goldberg Jeff Marc — President and CEO, DirectorGrant/award (A): 1,884,838 (derivative) @ $0EDGAR
2022-08-254Kastenmayer James Paul — Interim CEO & General CounselGrant/award (A): 130,000 (derivative) @ $0EDGAR
2022-08-254Souza Marcio — DirectorPurchase (P): 90,000 @ $0.56EDGAR
2022-08-254Sloan Leslie — Chief Operating OfficerGrant/award (A): 130,000 (derivative) @ $0EDGAR
2022-08-254Hanley Jr. Michael Conick — Chief Business OfficerGrant/award (A): 130,000 (derivative) @ $0EDGAR
2022-08-254Alspaugh Jonathan — Chief Financial OfficerGrant/award (A): 130,000 (derivative) @ $0EDGAR
2022-06-104Hanley Jr. Michael Conick — Chief Commercial OfficerPurchase (P): 28,200 @ $0.71EDGAR
2022-06-104Lawton Alison Frances — DirectorGrant/award (A): 43,000 (derivative) @ $0EDGAR
2022-06-094Shanafelt Armen — DirectorGrant/award (A): 43,000 (derivative) @ $0EDGAR
2022-06-094Souza Marcio — DirectorGrant/award (A): 43,000 (derivative) @ $0EDGAR
2022-06-094Smith Hunter C — DirectorGrant/award (A): 43,000 (derivative) @ $0EDGAR
2022-06-094Cox Russell J. — DirectorGrant/award (A): 43,000 (derivative) @ $0EDGAR
2022-06-094Mahatme Sandesh — DirectorGrant/award (A): 43,000 (derivative) @ $0EDGAR
2022-06-094Magovcevic-Liebisch Ivana — DirectorGrant/award (A): 43,000 (derivative) @ $0EDGAR
2022-06-094LAWLIS V BRYAN — DirectorGrant/award (A): 43,000 (derivative) @ $0EDGAR
2022-03-184Quinn Anthony G. — President & CEO, DirectorPurchase (P): 80,079 @ $2.34EDGAR
2022-03-154Alspaugh Jonathan — Chief Financial OfficerPurchase (P): 75,000 @ $2.08EDGAR
2022-03-154Quinn Anthony G. — President & CEO, DirectorPurchase (P): 34,777 @ $2.06 · Purchase (P): 67,472 @ $1.93 · Purchase (P): 42,417 @ $1.86EDGAR
2022-02-224Weber Steven — VP, Controller&Princ Acctg OffGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-02-224Sloan Leslie — Chief Operating OfficerGrant/award (A): 180,000 (derivative) @ $0EDGAR
2022-02-224Hanley Jr. Michael Conick — Chief Commercial OfficerGrant/award (A): 160,000 (derivative) @ $0EDGAR
2022-02-224Alspaugh Jonathan — Chief Financial OfficerGrant/award (A): 170,000 (derivative) @ $0EDGAR
2022-02-224Quinn Anthony G. — President & CEO, DirectorGrant/award (A): 350,000 (derivative) @ $0EDGAR
2021-12-134Shanafelt Armen — DirectorPurchase (P): 121,799 @ $3.67 · Purchase (P): 13,516 @ $3.65 · Purchase (P): 14,685 @ $3.65EDGAR
2021-12-134Alspaugh Jonathan — Chief Financial OfficerPurchase (P): 50,000 @ $3.72EDGAR
2021-12-134Quinn Anthony G. — President & CEO, DirectorPurchase (P): 43,108 @ $3.70 · Purchase (P): 10,526 @ $3.75EDGAR
2021-11-164Smith Hunter C — DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2021-08-184Alspaugh Jonathan — Chief Financial OfficerPurchase (P): 9,780 @ $6.37 · Purchase (P): 23,392 @ $6.50 · Purchase (P): 7,200 @ $6.72EDGAR
2021-07-084Alspaugh Jonathan — Chief Financial OfficerGrant/award (A): 160,000 (derivative) @ $0EDGAR
2021-06-224Souza Marcio — DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2021-06-104BAKER BROS. ADVISORS LP — Director
667, L.P. — Director
Baker Bros. Advisors (GP) LLC — Director
Baker Brothers Life Sciences LP — Director
BAKER FELIX — Director
BAKER JULIAN — Director
Grant/award (A): 40,000 (derivative) @ $0EDGAR
2021-06-094Mahatme Sandesh — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2021-06-094Magovcevic-Liebisch Ivana — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2021-06-094LAWLIS V BRYAN — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR

Recent 8-K events — Spyre Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-038-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-078-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-088-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-258-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-048-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-158-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-018-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-298-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-168-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=AGLE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs